Arvinas Inc. has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson’s Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Researchers from Pfizer reported preclinical efficacy of PF-08052667, an antibody-drug conjugate (ADC) targeting integrin β6 (ITGB6), in non-muscle-invasive bladder cancer (NMIBC) models.

TRIM21, an enzyme involved in intracellular substrate degradation, can recognize viruses and bacteria that enter the cytosol when they are coated with antibodies. Just as it tags complex molecules for elimination, it can direct these infectious microorganisms to lysosomes through a mechanism its discoverers have termed antibody-directed xenophagy (ADX). Scientists at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge, U.K., have identified the genes involved in this antibody-dependent degradation pathway, which acts as an antimicrobial process, and reported their findings in Molecular Cell on June 4, 2026.

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH) progression, where HSD17B13 exacerbates hepatic lipid metabolism, while CIDEB mainly mediates lipid droplet dynamics and storage. In this context, Frontier Biotechnologies Inc. has presented data on FB-7033, a bispecific siRNA approach targeting both HSD17B13 and CIDEB for the management of MASH.

Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic target. SKL-35501 is a novel 225Ac-labeled radiopharmaceutical developed by SK Biopharmaceuticals Co. Ltd. that targets NTSR1 for α-particle therapy.